FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Subscribe To Our Newsletter & Stay Updated